Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GMDTC in Healthy Subjects
NCT05908383Phase 1Completed
- Start
- Jan 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cadmium poisoning comparing GMDTC with Placebo (2 arms). Primary endpoints: Adverse events up to 30 days and Dose-Limiting Toxicity up to 1 week. Started Jan 2023; status: completed.
02
Drugs
gmdtc
03
Conditions
cadmium poisoning
Beyond the preview
Go deeper on NCT05908383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05908383.